The collaboration will initially focus on addressing interventions recommended for Medicare Advantage members of joint clients, but it may expand into additional services.
Altuviiio is an injectable medicine used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).
Lilly also will automatically cap out-of-pocket costs at $35 at participating retail pharmacies for people with commercial insurance using Lilly insulin.
